157 related articles for article (PubMed ID: 23426722)
1. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice.
MacKinnon AC; Liu X; Hadoke PW; Miller MR; Newby DE; Sethi T
Glycobiology; 2013 Jun; 23(6):654-63. PubMed ID: 23426722
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 Identifies a Subset of Macrophages With a Potential Beneficial Role in Atherosclerosis.
Di Gregoli K; Somerville M; Bianco R; Thomas AC; Frankow A; Newby AC; George SJ; Jackson CL; Johnson JL
Arterioscler Thromb Vasc Biol; 2020 Jun; 40(6):1491-1509. PubMed ID: 32295421
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I.
Reimers GJ; Jackson CL; Rickards J; Chan PY; Cohn JS; Rye KA; Barter PJ; Rodgers KJ
Cardiovasc Res; 2011 Jul; 91(1):37-44. PubMed ID: 21354994
[TBL] [Abstract][Full Text] [Related]
4. Nkx2-5 Is Expressed in Atherosclerotic Plaques and Attenuates Development of Atherosclerosis in Apolipoprotein E-Deficient Mice.
Du M; Wang X; Tan X; Li X; Huang D; Huang K; Yang L; Zhang F; Wang Y; Huang D; Huang K
J Am Heart Assoc; 2016 Dec; 5(12):. PubMed ID: 27993833
[TBL] [Abstract][Full Text] [Related]
5. Brussels Chicory Stabilizes Unstable Atherosclerotic Plaques and Reshapes the Gut Microbiota in Apoe-/- Mice.
Li Q; Zhang X; Du Y; Liu X; Chen G; Xiang P; Wu H; Liu C; Wang D
J Nutr; 2022 Oct; 152(10):2209-2217. PubMed ID: 35524685
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of extracellular cyclophilins with cyclosporine analog and development of atherosclerosis in apolipoprotein E-deficient mice.
Ditiatkovski M; Neelisetti VN; Cui HL; Malesevic M; Fischer G; Bukrinsky M; Sviridov D
J Pharmacol Exp Ther; 2015 Jun; 353(3):490-5. PubMed ID: 25788712
[TBL] [Abstract][Full Text] [Related]
7. Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease.
Biagioli M; Marchianò S; Di Giorgio C; Bordoni M; Urbani G; Bellini R; Massa C; Sami Ullah Khan R; Roselli R; Chiara Monti M; Morretta E; Giordano A; Vellecco V; Bucci M; Jilani Iqbal A; Saviano A; Ab Mansour A; Ricci P; Distrutti E; Zampella A; Cieri E; Cirino G; Fiorucci S
Biochem Pharmacol; 2023 Dec; 218():115900. PubMed ID: 37926268
[TBL] [Abstract][Full Text] [Related]
8. Caspase-11 deficiency attenuates neutrophil recruitment into the atherosclerotic lesion in apolipoprotein E-deficient mice.
Karasawa T; Komada T; Baatarjav C; Aizawa E; Mizushina Y; Fujimura K; Gunji Y; Komori S; Aizawa H; Jing Tao CB; Matsumura T; Takahashi M
Biochem Biophys Res Commun; 2023 Dec; 686():149158. PubMed ID: 37922574
[TBL] [Abstract][Full Text] [Related]
9. [Effects of canagliflozin on amino acid metabolism in atherosclerotic mice].
Zuo QJ; He LL; Ma S; Zhang GR; Zhang TT; Wang Y; Guo YF
Zhonghua Xin Xue Guan Bing Za Zhi; 2024 Jan; 52(1):64-71. PubMed ID: 38220457
[No Abstract] [Full Text] [Related]
10. Pectin: Health-promoting properties as a natural galectin-3 inhibitor.
An L; Chang G; Zhang L; Wang P; Gao W; Li X
Glycoconj J; 2024 Apr; 41(2):93-118. PubMed ID: 38630380
[TBL] [Abstract][Full Text] [Related]
11. Breaking barriers: How modified citrus pectin inhibits galectin-8.
Shuai M; Li Y; Guan F; Fu G; Sun C; Ren Q; Wang L; Zhang T
Food Funct; 2024 May; 15(9):4887-4893. PubMed ID: 38597504
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.
Suthahar N; Meijers WC; Silljé HHW; Ho JE; Liu FT; de Boer RA
Theranostics; 2018; 8(3):593-609. PubMed ID: 29344292
[TBL] [Abstract][Full Text] [Related]
13. NMR-based metabolomics of urine for the atherosclerotic mouse model using apolipoprotein-E deficient mice.
Leo GC; Darrow AL
Magn Reson Chem; 2009 Dec; 47 Suppl 1(0 1):S20-5. PubMed ID: 19565469
[TBL] [Abstract][Full Text] [Related]
14. Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment.
He Z; Chen W; Hu K; Luo Y; Zeng W; He X; Li T; Ouyang J; Li Y; Xie L; Zhang Y; Xu Q; Yang S; Guo M; Zou W; Li Y; Huang L; Chen L; Zhang X; Saiding Q; Wang R; Zhang MR; Kong N; Xie T; Song X; Tao W
Nat Nanotechnol; 2024 Jun; ():. PubMed ID: 38898135
[TBL] [Abstract][Full Text] [Related]
15. The Complex Biological Effects of Pectin: Galectin-3 Targeting as Potential Human Health Improvement?
Pedrosa LF; Raz A; Fabi JP
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204790
[TBL] [Abstract][Full Text] [Related]
16. Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus.
Ozturk D; Celik O; Satilmis S; Aslan S; Erturk M; Cakmak HA; Kalkan AK; Ozyilmaz S; Diker V; Gul M
Coron Artery Dis; 2015 Aug; 26(5):396-401. PubMed ID: 25887000
[TBL] [Abstract][Full Text] [Related]
17. Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis?
Aksan G; Gedikli Ö; Keskin K; Nar G; İnci S; Yıldız SS; Kaplan Ö; Soylu K; Kılıçkesmez KO; Şahin M
J Investig Med; 2016 Mar; 64(3):764-70. PubMed ID: 26912009
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 and post-myocardial infarction cardiac remodeling.
Meijers WC; van der Velde AR; Pascual-Figal DA; de Boer RA
Eur J Pharmacol; 2015 Sep; 763(Pt A):115-21. PubMed ID: 26101067
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis.
Madrigal-Matute J; Lindholt JS; Fernandez-Garcia CE; Benito-Martin A; Burillo E; Zalba G; Beloqui O; Llamas-Granda P; Ortiz A; Egido J; Blanco-Colio LM; Martin-Ventura JL
J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25095870
[TBL] [Abstract][Full Text] [Related]
20. Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice.
Lu Y; Zhang M; Zhao P; Jia M; Liu B; Jia Q; Guo J; Dou L; Li J
Mol Med Rep; 2017 Jul; 16(1):647-653. PubMed ID: 28560429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
